NanJing Pharmaceutical Company Limited Share Price

Equities

600713

CNE000000KV1

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 30/04/2024 am IST 5-day change 1st Jan Change
4.86 CNY +1.89% Intraday chart for NanJing Pharmaceutical Company Limited +3.40% +0.41%

Financials

Sales 2022 50.22B 6.94B 579B Sales 2023 53.59B 7.4B 617B Capitalization 6.34B 876M 73.07B
Net income 2022 596M 82.32M 6.87B Net income 2023 578M 79.84M 6.66B EV / Sales 2022 0.27 x
Net Debt 2022 6.94B 959M 79.98B Net Debt 2023 6.74B 931M 77.62B EV / Sales 2023 0.24 x
P/E ratio 2022
10.8 x
P/E ratio 2023
10.9 x
Employees 4,903
Yield 2022
2.73%
Yield 2023
3.31%
Free-Float 41.55%
More Fundamentals * Assessed data
Dynamic Chart
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds MT
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
NanJing Pharmaceutical Company Limited(XSSC:600713) added to S&P Global BMI Index CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
NanJing Pharmaceutical Company Limited entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd. CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
NanJing Medical’s Controlling Shareholder Boosts Stake to 44.2% For $158 Million MT
NanJing Pharmaceutical Company Limited announced that it has received CNY 997.999997 million in funding from Nanjing XinGong Investment Group Co., Ltd CI
More news
1 day+1.89%
1 week+3.40%
Current month+6.81%
1 month+6.81%
3 months+5.65%
6 months-1.22%
Current year+0.41%
More quotes
1 week
4.66
Extreme 4.66
4.89
1 month
4.45
Extreme 4.45
4.89
Current year
3.85
Extreme 3.85
5.03
1 year
3.85
Extreme 3.85
6.45
3 years
3.85
Extreme 3.85
6.45
5 years
3.85
Extreme 3.85
6.45
10 years
3.85
Extreme 3.85
20.50
More quotes
Managers TitleAgeSince
President 51 28/22/28
Director/Board Member 56 17/17/17
Director/Board Member 53 25/11/25
Members of the board TitleAgeSince
Chairman 58 21/19/21
Director/Board Member 53 25/11/25
Director/Board Member - 26/21/26
More insiders
Date Price Change Volume
30/24/30 4.86 +1.89% 17,152,900
29/24/29 4.77 +0.63% 11,033,340
26/24/26 4.74 +0.42% 9,599,606
25/24/25 4.72 +0.64% 7,231,702
24/24/24 4.69 -0.21% 6,393,612

End-of-day quote Shanghai S.E., April 30, 2024

More quotes
NanJing Pharmaceutical Company Limited is a China-based company principally engaged in the pharmaceutical distribution business. The Company's principal businesses include the pharmaceutical wholesale, pharmaceutical retail, pharmaceutical-Internet + business, as well as the pharmaceutical third-party logistics services. The Company mainly conducts its business in domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600713 Stock